EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 70 / Numéro 2 (Mars-Avril 2015) Therapie, 70 2 (2015) 157-165 Références
Numéro
Therapie
Volume 70, Numéro 2, Mars-Avril 2015
Addictovigilance : le défi pharmacologique de l'évaluation et de la prévention des substances à risque
Page(s) 157 - 165
Section Addictovigilance / Addictovigilance
DOI https://doi.org/10.2515/therapie/2015010
Publié en ligne 9 avril 2015
  1. Weisberg D, Stannard C. Lost in translation? Learning from the opioid epidemic in the USA. Anaesthesia 2013; 68: 1215-9 [CrossRef] [PubMed] [Google Scholar]
  2. Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther 2010; 88: 307-17 [CrossRef] [PubMed] [Google Scholar]
  3. Davis JM, Severtson SG, Bucher-Bartelson B, et al. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits. Pharmacoepidemiol Drug Saf 2014; 23: 18-25 [CrossRef] [PubMed] [Google Scholar]
  4. Cerda M, Ransome Y, Keyes KM, et al. Prescription opioid mortality trends in New York City, 1990-2006: examining the emergence of an epidemic. Drug Alcohol Depend 2013; 132: 53-62 [CrossRef] [PubMed] [Google Scholar]
  5. Nordmann S, Frauger E, Pauly V, et al. Post-marketing surveillance systems for psychoactive prescription drug abuse. Therapie 2011; 66: 263-72 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Pauly V, Frauger E, Pradel V, et al. Monitoring of benzodiazepine diversion using a multi-indicator approach. Int Clin Psychopharmacol 2011; 26: 268-77 [CrossRef] [PubMed] [Google Scholar]
  7. Lapeyre-Mestre M, Sapede C, Moore N, et al. Pharmacoepidemiology studies: what levels of evidence and how can they be reached? Therapie 2013; 68: 241-52 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  8. OICS. Rapport annuel de l’Organe International de Contrôle des Stupéfiants 2013. Nations Unies; 2014 http://www.incb.org/documents/Publications/AnnualReports/AR2013/French/AR_2013_F.pdf Accessed January 12th, 2015 (132 pages) [Google Scholar]
  9. OEDT. Annual report on the state of the drugs problem in Europe. In. Lisbon: EMCDDA; 2010 http://www.emcdda.europa.eu/publications/annual-report/2010 Accessed January 12th, 2015 [Google Scholar]
  10. Peyriere H, Eiden C, Micallef J, et al. Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. Eur Addict Res 2013;19: 235-44 [CrossRef] [PubMed] [Google Scholar]
  11. Bramness JG, Henriksen B, Person O, et al. A bibliometric analysis of European versus USA research in the field of addiction. Research on alcohol, narcotics, prescription drug abuse, tobacco and steroids 2001-2011. Eur Addict Res 2014; 20: 16-22 [CrossRef] [PubMed] [Google Scholar]
  12. European legal database on drugs http://www.emcdda.europa.eu/eldd Accessed January 12th, 2015 [Google Scholar]
  13. European database of suspected adverse drug reaction reports. http://www.adrreports.eu/ Accessed January 12th, 2015 [Google Scholar]
  14. Roussin A, Bouyssi A, Pouché L, et al. Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults: a cross-sectional investigation in France. PLoS One 2013; 8: e76499 [CrossRef] [PubMed] [Google Scholar]
  15. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res 2012; 18: 228-45 [CrossRef] [PubMed] [Google Scholar]
  16. Baumevieille M, Miremont G, Haramburu F, et al. The French system of evaluation of dependence: establishment in a legal system. Therapie 2001; 56: 15-22 [PubMed] [Google Scholar]
  17. Micaleff J, Jolliet P, Victorri-Vigneau C, et al. First meeting of the French CEIP (Centres d’Evaluation et d’Information sur la Pharmacodépendance): Assessment of the abuse and pharmacodependence potential during drug development. Therapie 2008; 63: 55-65 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  18. Micallef-Roll J, Lapeyre-Mestre M. Second meeting of the French CEIP (Centres d’Évaluation et d’Information sur la Pharmacodépendance). Part I: how to evaluate and prevent the abuse and dependence on hypnotic/anxiolytic drugs? Therapie 2009; 64: 355-64 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  19. Moracchini C, Frauger E, Pauly V, et al. Harm reduction centers (“CAARUD”): privileged places for warning signal detection in addictovigilance. Therapie 2012; 67: 437-45 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  20. Frauger E, Moracchini C, Le Boisselier R, et al. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol 2013; 27: 672-82 [CrossRef] [PubMed] [Google Scholar]
  21. Pradel V, Delga C, Rouby F, et al. Assessment of abuse potential of benzodiazepines from a prescription database using “doctor shopping” as an indicator. CNS Drugs 2010; 24: 611-20 [CrossRef] [PubMed] [Google Scholar]
  22. Micallef J, Pradel V, Thirion X, et al. Use of the health insurance database by the centres for evaluation and information on pharmacodependence: examples, interests and future prospects. Therapie 2004; 59: 581-8 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Frauger E, Pauly V, Pradel V, et al. Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundam Clin Pharmacol 2011; 25: 633-41 [CrossRef] [PubMed] [Google Scholar]
  24. Casati A, Piontek D, Pfeiffer-Gerschel T. Patterns of non-compliant buprenorphine, levomethadone, and methadone use among opioid dependent persons in treatment. Subst Abuse Treat Prev Policy 2014; 9: 19 [CrossRef] [PubMed] [Google Scholar]
  25. Giraudon I, Lowitz K, Dargan PI, et al. Prescription opioid abuse in the UK. Br J Clin Pharmacol 2013; 76: 823-4 [CrossRef] [PubMed] [Google Scholar]
  26. Lapeyre-Mestre M, Gony M, Carvajal A, et al. A European Community Pharmacy-Based Survey to Investigate Patterns of Prescription Fraud through Identification of Falsified Prescriptions. Eur Addict Res 2014; 20: 174-82 [CrossRef] [PubMed] [Google Scholar]
  27. EMCDDA publishes 2012 report on the state of the drugs problem in Europe. Euro Surveill 2012; 17 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20315 Accessed January 12th, 2015 [Google Scholar]
  28. Bersani FS, Corazza O, Simonato P, et al. Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy. Gen Hosp Psychiatry 2013; 35: 571-3 [Google Scholar]
  29. Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 2010; 110: 605-7 [PubMed] [Google Scholar]
  30. Grosshans M, Mutschler J, Hermann D, et al. Pregabalin abuse, dependence, and withdrawal: a case report. Am J Psychiatry 2010; 167: 869 [CrossRef] [PubMed] [Google Scholar]
  31. Olaizola I, Ellger T, Young P, et al. Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure 2006; 15: 208-10 [CrossRef] [PubMed] [Google Scholar]
  32. Yargic I, Ozdemiroglu FA. Pregabalin abuse: a case report. Klinik Psikofarmakologi Bülteni 2011; 21: 64-66 DOI: 10.5350/KPB-BCP201121110 [CrossRef] [Google Scholar]
  33. Gahr M, Franke B, Freudenmann RW, et al. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med 2013; 7: 147-9 [CrossRef] [PubMed] [Google Scholar]
  34. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 2014; 28: 491-6 [CrossRef] [PubMed] [Google Scholar]
  35. Schwan S, Sundström A, Stjernberg E, et al. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010; 66: 947-53 [CrossRef] [PubMed] [Google Scholar]
  36. Caster O, Edwards IR, Noren GN, et al. Earlier discovery of pregabalin’s dependence potential might have been possible. Eur J Clin Pharmacol 2011; 67: 319-20 [CrossRef] [PubMed] [Google Scholar]
  37. Micallef J, Frauger E, Palmaro A et al. Example of an investigation of an “emergent” phenomenon in addiction vigilance: the case of methylphenidate. Therapie 2015 DOI: 10.2515/therapie2015013 [Google Scholar]
  38. Gahr M, Freudenmann RW, Hiemke C, et al. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 2013; 69: 1335-42 [CrossRef] [PubMed] [Google Scholar]
  39. Fuzier R, Serres I, Guitton E, et al. Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database. Drug Saf 2013; 36: 55-62 [CrossRef] [PubMed] [Google Scholar]
  40. Aagaard L, Hansen EH. Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011. BMC Pharmacol Toxicol 2013; 14: 30 [CrossRef] [PubMed] [Google Scholar]
  41. Glaizal M, Gazin V, Aymard I, et al. Suicidal poisonings with methadone in France: results of a two year national survey by the Toxicovigilance network. Clin Toxicol (Phila) 2012; 50: 841-6 [CrossRef] [PubMed] [Google Scholar]
  42. Launiainen T, Broms U, Keskitalo-Vuokko K, et al. Nicotine, alcohol, and drug findings in young adults in a population-based postmortem database. Nicotine Tob Res 2011; 13: 763-71 [CrossRef] [PubMed] [Google Scholar]
  43. Häkkinen M, Vuori E, Kalso E, et al. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int 2014; 241: 1-6 [CrossRef] [PubMed] [Google Scholar]
  44. Lottner-Nau S, Övgüer B, Paul L, et al. Abuse of pregabalin-results of the post-mortem toxicology from 2010 to 2012. Toxichem Krimtech 2013; 80(special issue): 339-42 https://www.gtfch.org/cms/images/stories/media/tk/tk80_4/LottnerNauEtAl.pdf Accessed January 12th, 2015 (4 pages) [Google Scholar]
  45. Kriikku P, Wilhelm L, Rintatalo J, et al. Pregabalin serum levels in apprehended drivers. Forensic Sci Int 2014; 243: 112-6 [CrossRef] [PubMed] [Google Scholar]
  46. Schifano F, D’Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011; 80: 118-22 [CrossRef] [PubMed] [Google Scholar]
  47. Millar J, Sadasivan S, Weatherup N, et al. Lyrica nights–recreational pregabalin abuse in an urban emergency department. Emerg Med J 2013; 30: 874 DOI: 10.1136/emermed-2013-203113.20 [CrossRef] [Google Scholar]
  48. Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res 2014; 20: 115-8 [CrossRef] [PubMed] [Google Scholar]
  49. Grosshans M, Lemenager T, Vollmert C, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol 2013; 69: 2021-5 [CrossRef] [PubMed] [Google Scholar]
  50. Bramness JG, Sandvik P, Engeland A, et al. Does Pregabalin (Lyrica (®)) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol 2010; 107: 883-6 [PubMed] [Google Scholar]
  51. Wettermark B, Brandt L, Kieler H, et al. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract 2014; 68: 104-10 [CrossRef] [PubMed] [Google Scholar]
  52. Kapil V, Green JL, Le Lait MC, et al. Misuse of the gamma-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol 2014; 78: 190-1 [CrossRef] [PubMed] [Google Scholar]
  53. Boden R, Wettermark B, Brandt L, et al. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol 2014; 70: 197-204 [CrossRef] [PubMed] [Google Scholar]